Elusys and Pfizer Join Hands for New Therapeutics

January 24, 2007
BioPharm International Editors

Elusys Therapeutics, Inc. (Pine Brook, NJ, www.elusys.com), a biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections, has entered into an exclusive collaborative research and license agreement with Pfizer, Inc. (New York, NY, www.pfizer.com) to develop new therapeutics for select infectious diseases using Elusys's HP antibody technology.

Elusys Therapeutics, Inc. (Pine Brook, NJ, www.elusys.com), a biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections, has entered into an exclusive collaborative research and license agreement with Pfizer, Inc. (New York, NY, www.pfizer.com) to develop new therapeutics for select infectious diseases using Elusys’s HP antibody technology.

The research collaboration will include ETI-211, an HP Antibody for the treatment of methicillin-resistant Staphylococcus aureus infections, in addition to research into other indications. Under the terms of the agreement, Elusys and Pfizer will collaborate on determining the full product profile of ETI-211 and perform research on other indications of the HP Antibody technology. 

Elusys will receive an upfront equity investment, research and development funding, and near-term research milestones. Elusys has also granted Pfizer an option to acquire an exclusive worldwide license to products developed under the agreement, and upon exercise, the company will receive significant clinical and sales milestones, as well as royalties on future sales of products resulting from the collaboration.

Related Content:

News